Vical, Inc. (VICL)

carsondyle (30.99) Submitted: 11/9/2009 9:48:28 AM : Start Price: $3.03 VICL Score: -5.52

I like the pipeline. I think this is a long term buy, but in the short run stock may not make any dramatic moves. I also like SNGX if your looking for big gain potential next 6 to 12 months.

RootnToot (36.35) Submitted: 11/6/2009 12:18:28 PM : Start Price: $3.01 VICL Score: -3.30

Rolling the dice. After all, SOMEONE has to win the lottery, why not me?!!

crichton1 (35.28) Submitted: 10/8/2009 8:52:37 PM : Start Price: $3.86 VICL Score: -25.84

Good entry point for medical products approved next year.

AzUKHiker (< 20) Submitted: 10/1/2009 3:14:08 PM : Start Price: $4.03 VICL Score: -32.15

Stockscouter rating of 10 and high 3 and 12 month RS

NoDoughBro (70.80) Submitted: 8/31/2009 1:27:25 PM : Start Price: $3.00 VICL Score: -4.38

Because of the flu it's going to go woo...woo...wooo!

zzlangerhans (99.53) Submitted: 6/15/2009 12:48:50 PM : Start Price: $2.59 VICL Score: +4.34

I might have adopted a "wait and see" approach to Vical if it wasn't for the 100M picking threshold. I've been a green thumber on Vical before and had to watch it nearly go sub-1 before eventually squeaking out with a positive score. While Vical may be still be undervalued for the long term, the short term share price is too wrapped up in swine flu nonsense which I've been steadily betting against. Prior to swine flu, Vical was not very active in the pandemic influenza department and was focusing mainly on a CMV vaccine and the weird tumor vaccine Allovectin-7, neither of which was likely to rock the world anytime soon. Of course swine flu has made all of these companies influenza powerhouses long enough to get their stocks doubled and hopefully permit juicy dilutive financings. We shall see how all that works out for the shareholders.

KnowWhen2Holdem (< 20) Submitted: 7/6/2008 6:42:06 PM : Start Price: $3.52 VICL Score: -4.51

DNA plasmid technology for pandemic flu (results out in 8/08), peripheral artery disease partnered with ANGES (already approved in Japan) and SNY, Melanoma, CMV, etc. Other iron in fire is Vaxfectin as adjuvant for vaccines. Stock has gone from fantasy land pricing to reality. No current interest with slowly increasing volume and price. Very low capitalization (approximately 140 mm). This is one of those risky biotechs with big up and downside.

Macronomica (< 20) Submitted: 6/16/2008 7:16:50 AM : Start Price: $3.54 VICL Score: +1.78

Vical Pandemic Influenza Vaccines Provide Complete Protection in Animal Studies against H5N1

Vical announced today the publication of results demonstrating that pandemic influenza DNA vaccines formulated with the company's patented Vaxfectin(R) adjuvant provided complete protection of mice and ferrets against lethal challenge with a highly pathogenic strain of H5N1 influenza virus.

ipericles (75.94) Submitted: 3/13/2008 7:41:51 PM : Start Price: $3.34 VICL Score: +3.30

Company has innovative technologies that will make certain remedies (vaccines and the like) more effective in their intended use.

EtownDunk (24.80) Submitted: 10/27/2007 1:03:09 AM : Start Price: $5.19 VICL Score: -17.36

Nice Cash Flow Growth (TTM vs Prior), Good Oper Margin (TTM vs. 5yr) and relatively low Price/Book

tharlow (< 20) Submitted: 8/22/2007 3:28:35 AM : Start Price: $4.82 VICL Score: -17.36

Science will prevail.

Pluymen (< 20) Submitted: 1/29/2007 3:54:30 PM : Start Price: $6.32 VICL Score: -35.17

Anticipate a buyout by big pharma. If not, stock price will rise with positive news flow of trial results.

moorefish (< 20) Submitted: 11/19/2006 7:02:32 AM : Start Price: $6.43 VICL Score: -37.14

Out of fashion, but possibly amazing jabs on the way

deugei1 (74.07) Submitted: 10/22/2006 1:01:56 AM : Start Price: $5.93 VICL Score: -35.34

Great test results, and it's flu season.